Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management (Q34648346)

3 August 2017

1 reference

title

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management (English)

1 reference

3 August 2017

0 references

0 references

Emil Skamene

1 reference

3 August 2017

Michael A Gardam

1 reference

3 August 2017

Edward C Keystone

1 reference

3 August 2017

Richard Menzies

1 reference

3 August 2017

Steven Manners

1 reference

3 August 2017

Richard Long

1 reference

3 August 2017

Donald C Vinh

1 reference

3 August 2017

publication date

1 March 2003

1 reference

Lancet Infectious Diseases

3 August 2017

published in

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

148-155

1 reference

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

The role of cytokines in the immune response to tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Tumor necrosis factor: biology and therapeutic inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Restraining mycobacteria: role of granulomas in mycobacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Local role for tumor necrosis factor alpha in the pulmonary inflammatory response to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Expression of chemokines and induction of rapid cell death in human blood neutrophils by Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Tumor Necrosis Factor in the Malnutrition (Cachexia) of Infection and Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Assessment of a possible imbalance between tumor necrosis factor (TNF) and soluble TNF receptor forms in tuberculous infection of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

A role for lymphotoxin β receptor in host defense againstMycobacterium bovis BCG infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Etanercept therapy in children with treatment-resistant uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

Corticosteroids in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

1 reference

7 January 2021

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900545-0

7 January 2021

10.1016/S1473-3099(03)00545-0

Identifiers

DOI

1 reference

3 August 2017

1 reference